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In response to virus infection, type I interferons (IFNs)
induce several genes, most of whose functions are
largely unknown. Here, we show that the tripartite
motif (TRIM) protein, TRIM79a, is an IFN-stimulated
gene (ISG) product that specifically targets tick-
borne encephalitis virus (TBEV), a Flavivirus that
causes encephalitides in humans. TRIM79a restricts
TBEV replication by mediating lysosome-dependent
degradation of the flavivirus NS5 protein, an RNA-
dependent RNA polymerase essential for virus repli-
cation. NS5 degradation was specific to tick-borne
flaviviruses, as TRIM79a did not recognize NS5
fromWest Nile virus (WNV) or inhibitWNV replication.
In the absence of TRIM79a, IFN-b was less effective
in inhibiting tick-borne flavivirus infection of mouse
macrophages, highlighting the importance of a single
virus-specific ISG in establishing an antiviral state.
The specificity of TRIM79a for TBEV reveals a re-
markable ability of the innate IFN response to
discriminate between closely related flaviviruses.
INTRODUCTION
Flaviviruses have an essentially global distribution and represent
a tremendous disease burden to humans, causing millions of
infections annually. Significant members of this group include
dengue virus (DENV) and yellow fever virus (YFV) that cause
hemorrhagic fevers, as well as tick-borne encephalitis virus
(TBEV), Japanese encephalitis virus (JEV), and West Nile virus
(WNV) that cause severe encephalitides (Gould and Solomon,
2008; Robertson et al., 2009). Of significant threat to public
health, flaviviruses routinely emerge beyond their known
geographical range, including the spread of DENV and WNV in
the Americas and the increased recognition of various members
of the TBEV serocomplex throughout Europe, Asia, and North
America (Ebel, 2010; Mackenzie et al., 2004).Cell Host & MThe flavivirus single-stranded RNA genome is translated as
one open reading frame; the resulting polyprotein is cleaved
into at least ten proteins that include three structural (capsid
[C], membrane [M], and envelope [E]) and seven nonstructural
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). Virus
replication proceeds in association with modified membranes
derived from the endoplasmic reticulum (ER) of host cells (Fer-
nandez-Garcia et al., 2009). NS5 is the largest and most con-
served of the flavivirus proteins, containing 900 amino acids.
It encodes a methyltransferase (MTase) and RNA-dependent
RNA polymerase (RdRp) and associates with NS3 (the viral
protease) to form the functional unit of the viral replication
complex (RC) (Davidson, 2009; Kapoor et al., 1995).
In addition to its central role in RNA replication, NS5 is also the
most potent interferon (IFN) antagonist encoded by the flavivi-
ruses. NS5 inhibits IFN-a/b-dependent responses by preventing
JAK-STAT signaling and thus suppressing IFN-stimulated gene
(ISG) expression (Ashour et al., 2009; Best et al., 2005; Lau-
rent-Rolle et al., 2010; Lin et al., 2006; Mazzon et al., 2009;
Werme et al., 2008). Additionally, flaviviruses use NS5 to impede
ISG function by 20O methylation of the viral mRNA cap. This
disguises viral RNA from recognition by the IFIT family of proteins
(Daffis et al., 2010). Despite efficient antagonism of IFN re-
sponses by NS5 and other flavivirus proteins, type I IFN is effec-
tive in preventing flavivirus replication and in restricting tissue
tropism and mortality in mouse models of infection (Diamond,
2009). However, the molecular mechanisms by which IFN and
ISG expression suppress flavivirus replication are incompletely
understood.
Members of the tripartite motif (TRIM) family of proteins are
increasingly recognized as ISGs that mediate antiviral responses
(Nisole et al., 2005). TRIM proteins contain at least three distinct
domains, an N-terminal RING domain, one or two B boxes, and
a central coiled-coil domain. In addition, the C terminus of TRIM
proteins often contains a B30.2/SPRY domain that mediates
specific protein-protein interactions, although not all TRIM pro-
teins contain this domain (Ozato et al., 2008). An example of
the highly specific antiviral nature of TRIM proteins can be
observed in the case of TRIM5a restriction of retrovirus replica-
tion (Towers, 2007). Old World monkeys (OWM) are not suscep-
tible to productive infection with human immunodeficiency virusicrobe 10, 185–196, September 15, 2011 ª2011 Elsevier Inc. 185
Figure 1. TRIM79a Is an ISG Expressed during Virus Infection
(A) Schematic representations of yeast two-hybrid bait derived from LGTVNS5
(i) and prey cDNA of Trim79a (ii) identified from a murine macrophage library.
(iii) Diagram of the Trim79a promoter region with putative transcription factor
binding sites.
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HIV capsids, thereby accelerating uncoating and compromising
virus infectivity (Stremlau et al., 2004, 2006). However, restriction
of HIV replication by human TRIM5a is weak, likely contributing
to human susceptibility to infection. Species-specific restriction
of retrovirus replication is determined by amino acid differences
in the SPRY domain of different TRIM5a molecules; amino acid
divergence in viral capsid proteins determines viral sensitivity
to restriction (Johnson and Sawyer, 2009; Sawyer et al., 2005).
Thus, coevolution of TRIM proteins and viruses can influence
host tropism and virus pathogenesis.
The current study identifies a TRIM protein as an IFN-inducible
flavivirus restriction factor. This protein, denoted TRIM79a (also
known as TRIM30-3 or TRIM30D), interacted with NS5 from
Langat virus (LGTV; a member of the TBEV serogroup) and
TBEV and suppressed the replication of these viruses. However,
TRIM79a did not interact with WNV NS5, nor could it restrict
WNV replication, indicating a high degree of specificity. The
molecular mechanism of restriction was the direct targeting of
NS5 for degradation by lysosomes. Importantly, the antiviral
effects of IFN-b on tick-borne flavivirus replication were amelio-
rated by suppressing TRIM79a expression. Thus, TRIM79a is an
essential mediator of the IFN response specific to TBEV infection
through targeted destruction of the viral RNA polymerase and
major IFN antagonist.
RESULTS
TRIM79a Is an ISG Expressed during Virus Infection
The flavivirus NS5 protein is essential for virus replication, but
little is known about its molecular interactions with host proteins
involved in normal cellular function. Thus, we employed a yeast
two-hybrid analysis (MyriadGenetics, Salt LakeCity, UT) to iden-
tify potential cellular binding partners for NS5. Using various
baits derived from LGTV NS5, we found a potential interaction
between amino acids 1 and 248 or 40 and 260 of the LGTV
NS5 N terminus and a putative mouse protein AI451617 (amino
acids 95–498) from a mouse macrophage library (Figure 1A).
Sequence analysis by BLAST and PatternProt revealed that the
protein contained RING, B box, coiled coil (CC), and SPRY
domains and, therefore, belonged to the TRIM family and was
designated TRIM79a, with a denoting the full-length isoform.
To examine tissue distribution in vivo, we looked for Trim79a
mRNA by RT-qPCR in C57BL/6 mouse organs. Compared to
Trim79a mRNA levels in the skin, Trim79a mRNA was enriched(B) Trim79a mRNA expression in C57BL/6 mouse tissues assessed by
RT-qPCR. SC, spinal cord; LN, lymph node; and BM, bone marrow. Samples
are expressed relative to Trim79a mRNA level in the skin.
(C) Trim79a mRNA expression in RAW macrophages measured by RT-qPCR
at indicated times and graphed as fold induction relative to untreated control.
Stimuli: IFN-b (100 IU/ml), white bar; LGTV (MOI 10), black bar; and UV-irra-
diated LGTV (MOI 10), gray bar.
(D) Trim79amRNA expression measured by RT-qPCR in WT and Ifnar/ DCs
infected with LGTV (MOI 25), graphed as fold induction relative to uninfected
control.
(E) Trim79a mRNA expression measured by RT-qPCR in mouse cells (L929
and RAW) following SeV infection (200 HA units/ml), graphed as fold induction
relative to uninfected control.
See also Figure S1.
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Figure 2. TRIM79a Interacts with LGTV NS5
(A) Confocal microscopy of 293 cells expressing TRIM79a-GFP (green) and
LGTV proteins NS5, C, or NS4A (red).
(B) CoIP of lysates from 293 cells expressing TRIM79a-GFP or TRIM30a-GFP
with or without LGTV NS5-V5. Reciprocal IPs were performed using a-V5 or
a-GFP antibodies. M, mock transfected.
(C) CoIP of NS5 from 293 cells transfected with plasmids expressing
TRIM79a-GFP or GFP and infected with LGTV for 48 hr. The IP was performed
with IgY or a-NS5. IP and total protein (input) blots were probed with TBEV
(NS5)-, GFP (TRIM79a)-, or b-actin-specific antibodies. A molecular weight
marker is indicated in kDa.
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Cell Host & Min organs involved in immune regulation, including spleen, lymph
node, andbonemarrow, andwasdetectable in lungand liver (Fig-
ure 1B). This is reminiscent of the tissue distribution of TRIM30a,
the murine TRIM most similar to TRIM79a (Shi et al., 2008).
Many TRIM proteins are expressed in response to IFN or virus
infection (Rajsbaum et al., 2008). Consistent with these observa-
tions, the Trim79a promoter contains putative binding sites for
transcription factors involved in immune responses, including
nuclear factor kappa B (NFkB), STAT1, and IFN regulatory
factors (IRFs) (Figure 1A, iii). Thus, becausewe have been unsuc-
cessful in raising TRIM79a-specific antisera, we determined
Trim79a expression in various murine cell types in response to
IFN-b treatment, as well as during a productive LGTV or SeV
infection by RT-qPCR. Trim79a mRNA transcription was de-
tected by 4 hr post stimulation with 100 international units (IU)/
ml IFN-b in mouse macrophage RAW cells (Figure 1C). Similar
results were obtained in various mouse cells, including primary
DCs, L929 cells, and primary MEFs (Figure S1). Trim79a tran-
scriptional induction was dependent on LGTV replication in all
cells tested because UV-irradiated, replication-incompetent
virus failed to generate a Trim79a transcriptional response (Fig-
ure 1C and Figure S1). Additionally, Trim79a transcription in
response to LGTV infection relied upon IFN-dependent sig-
naling. DCs lacking the IFN-a/b receptor (Ifnar/) were virtually
devoid of a Trim79a response (Figure 1D) despite exhibiting
higher levels of LGTV replication (data not shown). Lastly, SeV,
a potent IFN inducer via IFN-b promoter stimulator-1 (IPS-1)
(Kumar et al., 2006), induced Trim79a transcription in L929 and
RAW cells, confirming that a nonflavivirus infection also invokes
Trim79a expression (Figure 1E). Collectively, these data demon-
strate that TRIM79a is an immune-related gene product that is
upregulated by type I IFN and virus infection.
TRIM79a Interacts with LGTV NS5
To confirm the interaction between LGTV NS5 and TRIM79a, we
first examined the cellular distribution of TRIM79a expressed
alone or with various LGTV proteins by confocal microscopy.
TRIM79a-GFP was distributed predominantly in distinct cyto-
plasmic bodies as well as more diffusely in the cytoplasm (Fig-
ure 2A). Coexpression of TRIM79a with LGTV NS5 leads to
a redistribution of NS5 from predominantly diffuse cytoplasmic
localization to punctate sites containing TRIM79a (Figure 2A).
This colocalization of TRIM79a with NS5 was specific, as other
viral proteins tested, including LGTV C and NS4A, did not coloc-
alize with TRIM79a (Figure 2A). To confirm a physical interaction
between NS5 and TRIM79a, we performed co-IP analyses
following cotransfection of TRIM79a-GFP and NS5-V5 ex-
pression plasmids. IP of NS5 with a-V5 antibody successfully
coprecipitated TRIM79a, but not the closely related TRIM30a
(Figure 2B). Likewise, the reciprocal experiment using a-GFP
antibody specifically coimmunoprecipitated NS5 with TRIM79a,
but not with TRIM30a (Figure 2B). To demonstrate this interac-
tion during LGTV replication, 293 cells were transfected with
either GFP or TRIM79a-GFP plasmids, infected with LGTV
(MOI 5), and assayed by co-IP using control or NS5-specific
IgY. TRIM79a coimmunoprecipitated with NS5 from LGTV-in-
fected samples using NS5-specific antibody, but not with the
control IgY (Figure 2C). Thus, TRIM79a can bind both ectopic
and endogenously expressed LGTV NS5 protein.icrobe 10, 185–196, September 15, 2011 ª2011 Elsevier Inc. 187
Figure 3. TRIM79a Protein Turnover Is Regulated by Proteasomal
Degradation
(A) Western blot analysis of lysates from 293 cells transfected with
TRIM79a-GFP or GFP plasmids and treated with CHX (100 mg/ml) for indicated
times (hr). TRIM79a-GFP blots were quantitated, normalized to b-actin, and
presented as proportion of TRIM79a remaining over time. Error bars represent
mean ± SEM from three experiments.
(B) Ubiquitination assay for Ub-modified TRIM79a. TRIM79a was affinity
purified from lysates of 293 cells expressing TRIM79a-V5/AP, with or without
HA-Ub or HA-SUMO1, and treated with DMSO or MG132 (10 mM) for 4 hr.
Conjugation of Ub or SUMO1 was visualized by probing blots with a-HA
antibody. Western blot of input is shown to demonstrate expression levels of
HA-Ub, SUMO1, and TRIM79a. M, mock transfected.
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Degradation
To understand the impact of TRIM79a on virus replication, we
first examined the normal processing of TRIM79a. We treated
293 cells expressing TRIM79a-GFP or GFP alone with CHX to
inhibit new protein synthesis (Figure 3A). Levels of TRIM79a
were normalized to b-actin and quantitated following western
blotting. TRIM79a had a rapid half-life between 1.5 and 2 hr (Fig-
ure 3A), similar to that reported for other TRIM family members
such as TRIM5a (Diaz-Griffero et al., 2006). To identify whether
TRIM79a turnover was ubiquitin (Ub) mediated, TRIM79a-V5/
AP was coexpressed with either HA-Ub or the related HA-
SUMO1. Cells were then treated with vehicle control (DMSO)
or proteasome inhibitor MG132 for 4 hr, and modified TRIM79a188 Cell Host & Microbe 10, 185–196, September 15, 2011 ª2011 Elwas assessed using the ubiquitination assay. TRIM79a was
conjugated to Ub, but not to SUMO1, and TRIM79a-Ub expres-
sion was stabilized by treatment with MG132 (Figure 3B). Inter-
estingly, SUMO1 expression resulted in reduced TRIM79a levels
in cell lysates, a phenomenon that was inhibited by MG132, sug-
gesting that some turnover of TRIM79amay be regulated by SU-
MOylation. However, there was no evidence that this was due to
direct SUMO1 modification of TRIM79a (Figure 3B). Thus,
normal turnover of TRIM79a is mediated by proteasomal degra-
dation, an event that ismost likely dependent on TRIM79a conju-
gation to Ub.
TRIM79a Expression Results in Proteasome-
Independent Degradation of NS5
To identify the consequence of NS5 interactions with TRIM79a,
the relative stability of NS5 was determined in the presence of
TRIM79a. Because TRIM79a is a rodent-specific TRIM protein
that is not expressed in human cells, 293 cells were used to
assay effects of TRIM79a in the absence of othermouse-specific
proteins. Increasing TRIM79a expression relative to NS5 re-
sulted in a dose-dependent decrease in NS5 levels (Figure 4A).
However, increasing NS5 levels in the presence of constant
TRIM79a expression did not markedly affect TRIM79a stability
(Figure 4A), suggesting that TRIM79a facilitates the degradation
of NS5.
To determine the degradation pathway used by TRIM79a, 293
cells expressing TRIM79a-GFP and NS5 were treated with
DMSO, MG132, NH4Cl (an inhibitor of lysosome acidification),
or 3-MA (an autophagy inhibitor). Surprisingly, we did not ob-
serve any rescue of NS5 with MG132 treatment, whereas
NH4Cl restored NS5 to control levels (Figure 4B), suggesting a
role for lysosomes. Autophagy is associated with lysosomal
degradation and can also be inhibited by NH4Cl. However,
despite effective inhibition of lithium-induced autophagosome
formation (data not shown), 3-MA led to a minimal rescue of
NS5 degradation (Figure S2A), suggesting that autophagy is
not the primary degradative pathway used by TRIM79a.
Due to the established role of the proteasome in normal
turnover of TRIM79a (Figure 3B), it was necessary to further eval-
uate the Ub-proteasome system in NS5 degradation. Loss of
NS5 through this mechanism would necessitate increased NS5
ubiquitination by TRIM79a. However, examination of NS5 ubiq-
uitination demonstrated the exact opposite; ubiquitinated NS5
stabilized by MG132 was lost in the presence of TRIM79a
(Figure 4C). Furthermore, expression of ubiquitin that lacks all
seven lysine residues (K0 Ub), making it incapable of chain
formation required for proteasome degradation (Lim et al.,
2005), enhanced TRIM79a protein levels without rescuing NS5
(Figure 4D). Finally, mutation of the TRIM79a RING catalytic
active site (C15,18A) did not prevent TRIM79a interaction with
NS5 (Figure S2B) or NS5 degradation (Figure S2C).Taken
together, these results strongly suggest that neither the protea-
some nor ubiquitination of NS5 by TRIM79a is required for NS5
degradation.
To confirm a role for the lysosome in NS5 degradation, we
used confocal microscopy to examine the localization of
TRIM79a/NS5 aggregates. Compared to cells expressing either
protein alone, LAMP1-positive lysosomes appeared to increase
in prevalence and colocalize with NS5 and TRIM79awhen thesesevier Inc.
Figure 4. TRIM79a Facilitates Proteasome-Independent Degradation of NS5
(A) Western blot analysis of lysates from 293 cells transfected with a constant amount of either LGTV NS5 or TRIM79a-GFP plasmid and increasing amounts of
the reciprocal plasmid. GFP vector plasmid was used to ensure equal DNA transfections. Quantitation of NS5 or TRIM79a expression normalized to actin is
presented below western blots as percent remaining.
(B)Western blot analysis of lysates from 293 cells transfected with a constant amount of LGTVNS5 and increasing amounts of TRIM79a-GFP plasmid. Cells were
treated with DMSO, MG132 (10 mM), or NH4Cl (20 mM) for 4 hr. Quantitation of NS5 expression was normalized to actin and presented as percent remaining.
(C) Ubiquitination assay and western blot analysis of lysates from 293 cells expressing LGTV NS5-V5/AP and HA-Ub with TRIM79a-GFP or GFP. Cells were
treated with DMSO or MG132 for 4 hr.
(D) Western blot analysis of lysates from 293 cells expressing LGTV NS5-V5 with TRIM79a-GFP or GFP and HA-Ub (WT) or HA-Ub-K0 (K0).
(E) Confocal microscopy of 293 cells expressing LGTV NS5 (red) and/or TRIM79a-GFP (green) and immunostained for endogenous LAMP1 (gray). Nuclei were
counterstained with DAPI (blue). White box designates area shown in inset.
(F) Western blot analysis of lysates from 293 cells stably expressing TRIM79a-GFP or GFP alone and transfected with indicated combinations of LGTV NS5-V5 or
NS2B/3-mCherry plasmids.
(G) Co-IP of TRIM79a-GFP (using a-GFP antibody) from 293 cells expressingTRIM79a-GFP or GFP alone and infected with LGTV (MOI 5) for 48 hr. Cells were
treated with NH4Cl (20 mM) for 12 hr prior to harvest to routinely detect NS3. IP and total protein (input) blots were probed with TBEV (NS5)-, NS3-, GFP-, or
b-actin-specific antibodies.
See also Figure S2.
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NS5 and TRIM79a was not inhibited by treatment with DMSO,
MG132, or 3-MA. However, consistent with the requirement
for lysosomes, NH4Cl treatment reduced NS5 colocalization
with TRIM79a at these sites (Figure S2D).
Lysosomes efficiently degrade large multiprotein complexes.
Hence, recruitment of NS5 to the lysosome may facilitate degra-
dation of proteins that interact with NS5. Thus, stability of the
NS3 protease with associated cofactor NS2B was examined in
the presence of TRIM79a. NS2B/3 protein levels were slightly
reduced in TRIM79a-expressing cells relative to control cells.
However, expression of NS5 in addition to TRIM79a resulted in
a pronounced loss of NS2B/3 (Figure 4F). TRIM79a protein levels
were also reduced following coexpressionwith both NS2B/3 and
NS5, which was not observed with NS5 alone. Finally, a complex
containing TRIM79a, NS5, and NS3 was confirmed during virus
replication (Figure 4G). Taken together, these data demonstrate
that TRIM79a facilitates proteasome-independent, lysosome-
mediated degradation of viral RCs through specific interaction
with NS5.
TRIM79a Expression Restricts LGTV Replication
Flaviviruses are dependent upon NS5 for critical functions during
virus replication (MTase, RdRP), as well as for its ability to inter-
fere with the host IFN response. Degradation of NS5 may there-
fore impact viral replication. To assay the effect of TRIM79a
expression on virus replication, we developed 293 clonal cell
populations that constitutively express either GFP or the
TRIM79a-GFP fusion protein. These cells were infected with
LGTV for 24 hr, and viral protein expression was assessed by
confocal microscopy. We observed a striking reduction in
virus-infected cells in TRIM79a-expressing 293 cells compared
to control cells (Figure 5A). Additionally, abundance of all viral
proteins, including NS5, NS3, and E, was lower in 293 cells
expressing TRIM79a (Figure 5B). Single (MOI 10) or multistep
(MOI 0.1, data not shown) growth curve analyses of LGTV dem-
onstrated that virus production was reduced in TRIM79a-
expressing cells by 60%–90% over 72 hr of infection (Figure 5C,
solid lines). This restriction was not dependent upon IFN expres-
sion, as higher IFN-b protein levels were detected in superna-
tants from control cells relative to TRIM79a-expressing cells
(Figure 5C, dotted lines).
To confirm that the mechanism of NS5 degradation during
LGTV replication was consistent with ectopic expression exper-
iments, 293/TRIM79a or GFP cells were infected with LGTV
followed by replacement of the inoculum with media containing
DMSO, MG132, lactacystin (a proteasome inhibitor), NH4Cl, or
3-MA at 2 hr post-infection (hpi). Only treatment with NH4Cl
prevented much of the loss of NS5 observed in TRIM79a cells
at 48 hpi and relieved TRIM79a-mediated restriction of LGTV
replication (Figure 5D). These data confirm that TRIM79a is an
antiviral factor that inhibits virus replication by lysosomal target-
ing of the viral polymerase NS5.
TRIM79a Is a Restriction Factor Specific
for the Tick-Borne Flaviviruses
TRIM family members can recognize viral proteins in a virus- and
host species-specific fashion (Nisole et al., 2005). Thus, it is of
interest to determine whether TRIM79a suppresses replication190 Cell Host & Microbe 10, 185–196, September 15, 2011 ª2011 Elof other flaviviruses. Confocal microscopy demonstrated coloc-
alization between TRIM79a and NS5 derived from TBEV (Fig-
ure 6A), but not with NS5 proteins from the mosquito-borne
WNV or JEV. Consistent with this, TRIM79a interacted with
NS5 from TBEV, but not with NS5 from WNV or JEV (Figure 6B).
To determine the specificity of TRIM79a as a restriction factor,
the replication of TBEV (strain Sofjin) or WNV (strain NY99) was
compared in 293/TRIM79a-GFP and control cells. In agreement
with the lack of interaction with NS5, replication of WNV NY99
(Figure 6C) was not impaired in TRIM79a-expressing cells,
whereas TBEV replication was significantly reduced at 24 and
48 hpi (Figure 6D). Similar restriction was observed for the tick-
borne Powassan virus (POWV) (data not shown). Taken together,
these results demonstrate that the function of TRIM79a as
an antiviral molecule is specific to viruses belonging to the
TBEV serocomplex and is mediated through direct interaction
with NS5.
TRIM79aExpression Is Required for theAntiviral Effects
of IFN-b on TBEV Replication
To assess the importance of TRIM79a in the host IFN response
to TBEV infection, we used replication-defective lentiviruses to
deliver short hairpin RNA (shRNA) directed against Trim79a
(TRIM79sh) or a GFP-silencing control (GFPsh) into mouse
macrophages (RAW cells). To examine knockdown efficiency,
transduced cells were treated with IFN-b and mRNA expression
corresponding to Trim79a and Trim30a was measured by RT-
qPCR. Trim79a knockdown was greater than 90% and was
specific, as it did not decrease Trim30a mRNA expression (Fig-
ure 7A). Transduced RAW cells were infected with LGTV (Fig-
ure 7B) or TBEV Sofjin (Figure 7C), treated with 100 IU/ml
IFN-b at 6 hpi, and virus production was measured by immuno-
focus assay at 48 hpi. In the absence of exogenously added
IFN-b, virus replication was not significantly affected by suppres-
sion of TRIM79a expression, consistent with low basal levels of
Trim79a mRNA. However, the antiviral effect of IFN-b treatment
was abrogated following TRIM79a knockdown, as evidenced by
higher virus replication in the presence of IFN-b (Figures 7B and
7C). These results demonstrate that TRIM79a is an essential
effector molecule of the IFN response to TBEV.
DISCUSSION
The current study has identified a highly virus-specific TRIM
protein, TRIM79a, as a key mediator of the innate cellular
response to TBEV infection. Trim79a expression was dependent
on type I IFN and was required for effective restriction of TBEV
replication by IFN-b. The mechanism of TRIM79a-dependent
restriction of TBEV was direct, targeting NS5, the viral poly-
merase and an essential component of the RC, for degradation.
The few TRIM proteins previously demonstrated to have direct
antiviral activity, including TRIM5a and TRIM22, generally
require the RING domain andmay use the proteasome to restrict
virus replication (Barr et al., 2008; Diaz-Griffero et al., 2007; Eldin
et al., 2009; Gao et al., 2009; Maegawa et al., 2010; Wu et al.,
2006). However, TRIM79amediated degradation of NS5 through
lysosomes independently of the RING catalytic site. TRIM79a-
mediated restriction was specific to flaviviruses belonging to
the TBEV serogroup because NS5 derived from the mosquito-sevier Inc.
Figure 5. TRIM79a Expression Restricts LGTV Replication
(A) Confocal microscopy of 293/TRIM79a-GFP or 293/GFP cells (green) infected with LGTV (24 hpi, MOI 10) and immunostained for NS3 (red). White box
designates area shown in inset.
(B) Western blot analysis of lysates from clonal 293/TRIM79a-GFP or 293/GFP cells infected with LGTV (MOI 0.1) for indicated times (hr). Blots were probed with
antibodies specific to LGTV NS5, NS3, and E proteins, as well as TRIM79a (GFP) and actin.
(C) Titration of LGTV infectious particles in supernatants from clonal 293/TRIM79a-GFP and 293/GFP cells infected with LGTV (MOI 10) for indicated times (hr,
solid lines/left y axis). Data are representative of multiple independent experiments performed in triplicate and plotted as mean ± SEM. *p < 0.05. These data are
also presented as the percent replication of LGTV in 293/TRIM79a-GFP cells observed in three independent experiments plotted relative to 293/GFP control cells.
IFN-b protein in supernatants from infected cells quantitated by ELISA is represented by dotted lines (right y-axis).
(D)Western blot analysis of NS5 and TRIM79a expression in clonal 293/GFP cells (G) and 293/TRIM79a-GFP (T) infected with LGTV (MOI 0.1) for 48 hr. Cells were
treated at 2 hpi with DMSO,MG132 (0.1 mM), lactacystin (0.1 mM), NH4Cl (20mM), or 3-MA (1mM) supplementedmedia. LGTV infectious particles in supernatants
from these experiments were titrated by immunofocus assay and presented as percent replication relative to 293/GFP control cells. Data are representative of
two independent experiments performed in triplicate and plotted as mean ± SEM. *p < 0.05; **p < 0.01.
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and WNV replication was unimpeded by TRIM79a expression.
This high degree of specificity demonstrated by TRIM79a re-
veals a remarkable ability of the innate IFN response to discrim-
inate between closely related flaviviruses.
Ectopic expression of TRIM79a in 293 cells resulted in a 50%–
90% reduction of both LGTV and TBEV replication despite the
fact that TRIM79a expression resulted in lower expression of
IFN-b. The degree of inhibition observed here is highly reminis-
cent of similar experiments evaluating virus restriction by pro-
teins with dominant roles in IFN-dependent antiviral responses.
Notable examples of these proteins include P56 inhibition ofCell Host & Mhuman papilloma virus (Terenzi et al., 2008), IRF-1 as a general
antiviral molecule (Schoggins et al., 2011), and 20-50-oligoadeny-
late synthetase 1b (OAS1b), encoded by the flavivirus resistance
gene Flv. In the latter case, ectopic expression of OAS1b in cells
derived from susceptible mice results in 50% reduction in
WNV titers. However, WNV titers in resistant mice are 103- to
104-fold lower than in susceptible mice (Perelygin et al., 2002).
Although a limited number of additional gene products may
contribute to flavivirus susceptibility, the Flv studies suggest
that in vitro experiments examining ectopically expressed pro-
tein may underestimate the importance of individual ISGs in
controlling virus replication in vivo.icrobe 10, 185–196, September 15, 2011 ª2011 Elsevier Inc. 191
Figure 6. TRIM79a Specifically Interacts with NS5 from Tick-Borne Flaviviruses and Restricts TBEV Replication
(A) Confocal microscopy of 293 cells expressing TRIM79a-GFP (green) and NS5 derived from LGTV, TBEV, WNV, or JEV (red).
(B) Co-AP of TRIM79a-AP/V5 from 293 cells transfected with TRIM79a-V5/AP and indicated flavivirus NS5-V5 plasmids. Blots were probed with a-V5 and
TRIM79a-AP/V5, and NS5-V5 were differentiated by mobility.
(C and D) Quantification of virus replication by immunofocus assay in clonal 293/TRIM79a-GFP or 293/GFP cells infected with WNV NY99 (C) or TBEV Sofjin (D)
at an MOI of 10 FFU/cell for indicated times (hr). Data are representative of three independent experiments performed in triplicate and plotted as mean ± SEM.
*p < 0.05; **p < 0.01.
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Restriction of TBEV by TRIM79aLysosomes are cellular organelles that are critical for macro-
molecule degradation and are the final destination of material
undergoing phagocytosis, endocytosis, or autophagy (Schro¨der
et al., 2010). Thus, a switch from proteasome-dependent degra-
dation of normal TRIM79a to lysosome-dependent degradation
of NS5 observed in this study may represent an antiviral mecha-
nism to target large protein complexes for destruction. In
support of this, TRIM79a facilitated the degradation of protein
complexes containing at least NS5, NS2B, and NS3. However,
despite the fact that NS5 is expressed on the cytosolic side of
ER membranes, flavivirus RCs are shielded by virus-generated
membrane proliferations that are thought to prevent recognition
of viral replication intermediates by the host cell (Hoenen et al.,
2007; Overby et al., 2010). NS5 is also anchored to membranes
through its interactions with other viral NS proteins. Thus, it is
unclear how TRIM79a would access NS5 in RCs and transport192 Cell Host & Microbe 10, 185–196, September 15, 2011 ª2011 Elit to lysosomes. We did not find clear evidence that TRIM79a
functions in concert with autophagy to drive destruction of the
TBEV RC. Therefore, further studies will be required to elucidate
the precise mechanism by which TRIM79a mediates TBEV
restriction.
Although central to viral RC function, not all NS5 produced
during flavivirus replication is found in membrane-bound RCs.
NS5 is also present free in the cytoplasm or nucleus of cells
infected with some flaviviruses (Davidson, 2009). Thus, multiple
populations of NS5 exist over the course of infection that
function indirectly in virus replication by modulating cellular pro-
cesses such as suppression of IFNa/b-dependent signal trans-
duction or host gene expression (Medin et al., 2005). These pop-
ulations can be defined by the viral and cellular proteins bound to
NS5 or by posttranslational modifications such as phosphoryla-
tion and ubiquitination.We observed at least two species of NS5,sevier Inc.
Figure 7. Trim79a Expression Is Required for the Antiviral Effects of
IFN-b on TBEV Replication
(A) Trim79a and Trim30a mRNA expression measured by RT-qPCR in RAW
cells transduced with TRIM79a or GFP shRNA lentiviruses, treated with IFN-b
(100 IU/ml), and normalized to Hprt mRNA. mRNA expression levels are
relative to IFN-b-treated RAW/GFPsh cells.
(B and C) Titration of infectious LGTV (B) or TBEV Sofjin (C) particles in
supernatants from RAW cells transduced with TRIM79a or GFP shRNA lenti-
viruses and either mock treated or treated with IFN-b (100 IU/ml) at 6 hpi. Virus
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Cell Host & Ma nonubiquinated form and a Ub-conjugated form that was
stabilized by MG132. Thus, NS5 degradation occurs by at least
two pathways, the TRIM79a-dependent lysosome and the
TRIM79a-independent proteasome. The presence of separable
populations of NS5 suggests that TRIM79a may also target a
population involved in functions other than in the RC. Under-
standing the molecular determinants required for TRIM79a
recognition of TBEV NS5 would help illuminate the complexity
of NS5 function in virus replication and pathogenesis.
The structure of NS5 is highly conserved between flaviviruses
despite the fact that NS5 proteins share only 40% identity at
the amino acid level. The discovery of TRIM79a by yeast
two-hybrid analysis of the NS5 MTase domain suggests that
differences within this domain between TBEV and WNV may
determine specificity and will be the subject of future studies.
We also demonstrated a further level of specificity in TRIM
recognition, as TRIM30a shares 82% identity with TRIM79a
but failed to directly interact with LGTV NS5. Taken together,
these observations suggest that the NS5/TRIM79a interaction
exists as a consequence of virus-host coevolution. The enzootic
transmission cycle of TBEV occurs predominantly between tick
vectors and their rodent hosts without causing obviousmorbidity
in the rodent (Bakhvalova et al., 2009; Ebel, 2010). This clearly
differentiates the evolutionary pressures of TBEV from those of
WNV and JEV that cycle between mosquitoes and either birds
or pigs (Mackenzie et al., 2004; van denHurk et al., 2009). Hence,
suppression of TBEV replication by the rodent-specific TRIM79a
may represent an example of virus-host coevolution whereby
type I IFN dampens virus replication, thereby contributing to
reservoir host tropism and virus maintenance in nature.
For every antiviral measure utilized by the host, viruses have
evolved strategies of evasion. TBEV delays production of type
I IFN (Overby et al., 2010) and antagonizes IFN signaling (Best
et al., 2005; Werme et al., 2008), strategies that would suppress
TRIM79a expression. In addition, TRIM79a protein levels may be
a target of virus antagonism. A loss in TRIM79a protein was
evident late in infection with LGTV coincident with the detection
of viral proteins by western blot (Figure 5B). A similar reduction in
TRIM79a was seen in the presence of both NS5 and NS2B/3
(Figure 4F). TRIM79a does not appear to be degraded with
NS5 in the lysosome, as only proteasome inhibitors could stabi-
lize TRIM79a expression and ectopically expressed NS5 did not
impact TRIM79a levels. A protein complex containing TRIM79a
and NS5 may simply be degraded more efficiently in the pres-
ence of NS2B/3. However, because NS2B/3 is the viral protease,
TBEV may also evade restriction through the cleavage and
inactivation of TRIM79a. A similar phenomenon was recently
reported for TRIM56-mediated restriction of bovine viral diarrhea
virus (BVDV), a Pestivirus and member of the Flaviviridae family.
Though the viral target of TRIM56 is unknown, expression of
the BVDV small N-terminal protease (Npro) was associated with
reduced TRIM56 protein levels, suggesting that Npro might
directly antagonize this TRIM (Wang et al., 2011). Hence, inter-
ference of TRIM function may be an unexplored mechanismproduction was measured by immunofocus assay at 48 hpi. Data are the
average of three (LGTV) or two (TBEV Sofjin) independent experiments per-
formed in triplicate and plotted as mean ± SEM. *p % 0.05; **p < 0.01; ns,
nonsignificant.
icrobe 10, 185–196, September 15, 2011 ª2011 Elsevier Inc. 193
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pathogenesis.
In addition to direct roles in virus restriction, TRIM proteins
are required to regulate signaling pathways such as Toll-like
receptors (TLRs) and RIG-I-like receptors (RLR) leading to virus
detection and innate immune responses (Ozato et al., 2008).
Both TRIM79a and TRIM30a have been linked to lysosomal
degradation of the signaling components TAB2 and TAB3 (Shi
et al., 2008; Tareen and Emerman, 2011), thus acting as negative
regulators of the TLR/NFkB pathway. This function is consistent
with reduced IFN-b expression observed during LGTV replica-
tion in TRIM79a-expressing cells. As has been demonstrated
for influenza NS1 that binds to TRIM25 to inhibit RIG-I activity
(Gack et al., 2009), the function of NS5-bound TRIM79a may
provide a benefit to TBEV replication in vivo. For example,
suppression of TRIM79a cellular function may increase produc-
tion of inflammatory cytokines to recruit monocytes and macro-
phages to sites of infection and facilitate TBEV transmission
to feeding ticks or dissemination in the vertebrate host. Alterna-
tively, NS5 may potentiate TRIM79a function to suppress IFN
expression. Experiments are currently in progress to evaluate
the impact of TBEV infection and NS5 expression on the cellular
roles of TRIM79a.
Despite the importance of host IFNa/b responses in the con-
trol of flavivirus infections, IFN is ineffective as a clinical therapy,
likely compromised by virus-encoded antagonists of IFN-depen-
dent JAK-STAT signaling (Robertson et al., 2009). Thus, under-
standing the precise antiviral mechanisms of ISGs may enable
development of therapeutics effective against viruses like the
flaviviruses that have evolved to target IFN-dependent signal
transduction. Moreover, although hundreds of antiviral genes
are expressed in response to IFN, this work demonstrates that
antiviral activity can be tailored to individual pathogens by the
activity of virus-specific ISGs. The fact that the TRIM proteins
often target necessarily conserved structures such as the viral
RNA polymerase suggests that resistance to TRIM mimetics as
therapeutics may not be easily acquired through virus mutation.
Therefore, further studies to identify additional TRIM molecules
that specifically target flaviviruses, as well as to understand
TRIM mechanisms of restriction, are warranted.EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
HEK293 (293), L929, Vero, and RAW 264.7 (RAW) cells (ATCC) were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
(vol/vol) fetal calf serum (Gibco), 100 units/ml penicillin, and 100 mg/ml strep-
tomycin (Invitrogen) in an atmosphere of 5% CO2 at 37
C. Cell culture grade
MG132, ammonium chloride (NH4Cl), 3-methyladenine (3-MA), N-ethylmalei-
mide (NEM), puromycin, G418, polybrene, cycloheximide (CHX), and dimethyl
sulfoxide (DMSO) were purchased from Sigma. Murine IFN-b and granulocyte
macrophage-colony-stimulating factor (GM-CSF) were obtained from R&D
Systems. The generation and culture of mouse bonemarrow-derived dendritic
cells (DCs) andmouse embryo fibroblasts (MEFs) are described in the Supple-
mental Experimental Procedures.
Antibodies
The following antibodies were used: a-actin (A5441, Sigma); a-GFP (JL-8,
Clontech); a-dsRed (632496, Clontech); a-V5 (R960-25, Invitrogen); a-HA
(16B12, Covance); a-lysosome-associated membrane protein 1 (LAMP1)
(ab24170, Abcam); a-TBEV (RSSE VR79; ATCC); LGTV E (from Dr. C. Schmal-194 Cell Host & Microbe 10, 185–196, September 15, 2011 ª2011 Eljohn, USAMRIID); WNV E (from Dr. R. Tesh, World Reference Center for
Emerging Viruses and Arboviruses [WRCEVA], UTMB); affinity-purified
chicken antibodies specific for LGTV NS5 peptides (sequence: CZ
DRHDLHWELKLESSIF); NS3 (sequence: CZRDIREFVSYASGRR); and control
IgY antisera (custom prepared by Aves Labs).
Virus Infections
The following viruses were used in this study: LGTV strain TP21 (Dr. A. Pletnev,
NIAID, NIH),TBEV strain Sofjin (also known as Russian spring summer enceph-
alitis [RSSE] virus; from Dr. M. Holbrook, NIAID, NIH), POWV and WNV strain
NY99 (from the WRCEVA); and Sendai virus (SeV, Cantell strain; Charles River
Laboratories). Flavivirus working stocks were propagated and titrated by
immunofocus assay on Vero cells. Multiplicity of infection (MOI) for wild-type
or equivalent UV-irradiated (360 mJ/cm2 in a Stratalinker) flavivirus infections
is represented as focus-forming units (FFU) per cell. All procedures with
WNV and POWV were performed under biosafety level-3 (BSL-3) conditions;
procedures with TBEV were performed under BSL-4 conditions at the Rocky
Mountain Laboratories Integrated Research Facility (Hamilton, MT). Lentivirus
generation for gene knockdown studies is described in the Supplemental
Experimental Procedures.
Plasmids and Transfections
Trim79a (10470120) and Trim30a (MGC-6159) cDNA clones were obtained
from ATCC. LGTV NS2B/3 was derived from PCR amplification using the
LGTV E5 molecular cDNA clone as template (from Dr. A. Pletnev, NIAID,
NIH). Each gene was PCR amplified and directionally cloned into the Gateway
entry vector pENTR/SD/D-TOPO (Invitrogen). Entry vectors derived from
LGTV, WNV (strain NY99), JEV (strain Nakayama), and TBEV (strain Hypr)
NS5 were previously described (Laurent-Rolle et al., 2010). Mammalian ex-
pression plasmids were then obtained by recombination into various Gateway
destination vectors: pcDNA6.2/V5-DEST (C-terminal V5 tag); pcDNA-3.2/cap-
TEV-NT/V5-DEST (N-terminal V5/AP tag); pcDNA-3.2/capTEV-CT/V5-DEST
(C-terminal V5/AP tag); pDS_GFP-XB (N-terminal GFP tag, ATCC); and
pcDNA6.2-mCherry-C-DEST (C-terminal mCherry tag, from Dr. S. Grieshaber,
University of Florida). Plasmids used in this study express N-terminal tagged
TRIM proteins and C-terminal tagged NS5 and NS2B/3 proteins. Site-directed
mutagenesis was performed using QuikChange XL kit (Stratagene) according
to manufacturer’s protocol. All plasmids and mutations were verified by DNA
sequencing. Additional plasmids used were: pRK5-HA-ubiquitin (Ub)-WT
and K0 (Addgene plasmids 17608 and 17603; from Dr. T. Dawson, Johns
Hopkins University) and pcDNA3-HA-SUMO1 (small Ub-like modifier 1; from
Dr. M. White, UT Southwestern). Cell transfections were performed according
to manufacturer’s protocol in 6-well plates or 8-well Lab Tek II chamber slides
(Nunc) using Lipofectamine LTX and OptiMEM (Invitrogen) and allowed to
recover at least 24 hr prior to assay. Stable 293 cell lines were selected
24 hr posttransfection with G418 (400 mg/ml). Selected cell pools were serially
diluted, and stable clones were identified by western blot and RT-qPCR
described in the Supplemental Experimental Procedures.
Coimmunoprecipitation and Coaffinity Purification
293 cells were washed twice with DPBS and lysed by three freeze-thaw cycles
in immunoprecipitation (IP) buffer (50 mM Tris-HCl [pH 7.5], 150 mMNaCl, 1%
NP-40, and 0.5% Na-deoxycholate) with protease inhibitor cocktail (Roche).
Samples were subjected to centrifugation for 10 min to remove cellular debris.
Cell lysates were then cleared by addition of protein G-conjugated agarose
beads (Roche) or PrecipHen for chicken antibodies (Aves) and rotated at
4C for 3 hr. Beads were removed by centrifugation, and antibody (2 mg)
corresponding to the protein of interest was added to each lysate for 1 hr
with rotation at 4C. Protein G-agarose or PrecipHen beads were again added,
and lysates were incubated with rotation at 4C overnight. Lysates were dis-
carded after a brief centrifugation, and beads were washed twice with IP buffer
and twice with RIPA buffer prior to elution by incubation at 95C in 13 sample
buffer (62.5 mM TRIS [pH 6.8], 10% glycerol, 15 mM EDTA, 4% 2-ME, 2%
SDS, and bromophenol blue). Coaffinity purifications (Co-AP) were performed
as for coimmunoprecipitations (Co-IPs) with the following exceptions. The
expression plasmid (pcDNA-3.2/capTEV-NT or CT/V5-DEST) contains a V5
tag and also enables target protein biotinylation by the eukaryotic cellular
machinery during expression, referred to as V5/AP tag. Samples weresevier Inc.
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(Sigma), and incubated with streptavidin-agarose (Invitrogen) overnight with
rotation at 4C. Washes were identical to Co-IP. Cell lysates were eluted by
heating at 95C for 5 min in 23 sample buffer. Co-IP and Co-AP assays
were evaluated by western blotting.
Ubiquitination Assays
Ubiquitination assays were modified from the Co-AP by the addition of NEM to
lysis buffer to prevent deubiquitinase (DUB) activity and heating samples at
95C for 5 min prior to affinity purification in 1% SDS to remove interacting
proteins. HA-tagged Ub or SUMO1 plasmids were also cotransfected to
enable efficient detection of modified proteins. Following co-AP, Ub-modified
proteins were examined by western blotting.
Antibody-Based Techniques
Immunofocus assays, ELISA, and immunofluorescent confocal microscopy
are described in the Supplemental Experimental Procedures.
Statistical Analysis
Data were analyzed by a one-tailed unpaired t test or Mann-Whitney U test
using GraphPad Prism 5 software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and two figures and can be found with this article online at doi:10.1016/
j.chom.2011.08.004.
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